VOC-based detection of prostate cancer using an electronic nose and ion mobility spectrometry: A novel urine-based approach.
diagnostics
electronic nose
ion mobility spectrometry
smell prints
Journal
The Prostate
ISSN: 1097-0045
Titre abrégé: Prostate
Pays: United States
ID NLM: 8101368
Informations de publication
Date de publication:
18 Mar 2024
18 Mar 2024
Historique:
received:
24
01
2024
accepted:
07
03
2024
medline:
18
3
2024
pubmed:
18
3
2024
entrez:
18
3
2024
Statut:
aheadofprint
Résumé
Many diseases leave behind specific metabolites which can be detected from breath and urine as volatile organic compounds (VOC). Our group previously described VOC-based methods for the detection of bladder cancer and urinary tract infections. This study investigated whether prostate cancer can be diagnosed from VOCs in urine headspace. For this pilot study, mid-stream urine samples were collected from 56 patients with histologically confirmed prostate cancer. A control group was formed with 53 healthy male volunteers matched for age who had recently undergone a negative screening by prostate-specific antigen (PSA) and digital rectal exam. Headspace measurements were performed with the electronic nose Cyranose 320 The electronic nose yielded a sensitivity of 77% and specificity of 62%. Mahalanobis distance was 0.964, which is indicative of limited group separation. IMS identified a total of 38 individual analytical peaks, two of which showed significant differences between groups (p < 0.05). To discriminate between tumor and controls, a decision tree with nine steps was generated. This model led to a sensitivity of 98% and specificity of 100%. VOC-based detection of prostate cancer seems feasible in principle. While the first results with an electronic nose show some limitations, the approach can compete with other urine-based marker systems. However, it seems less reliable than PSA testing. IMS is more accurate than the electronic nose with promising sensitivity and specificity, which warrants further research. The individual relevant metabolites identified by IMS should further be characterized using gas chromatography/mass spectrometry to facilitate potential targeted rapid testing.
Sections du résumé
BACKGROUND
BACKGROUND
Many diseases leave behind specific metabolites which can be detected from breath and urine as volatile organic compounds (VOC). Our group previously described VOC-based methods for the detection of bladder cancer and urinary tract infections. This study investigated whether prostate cancer can be diagnosed from VOCs in urine headspace.
METHODS
METHODS
For this pilot study, mid-stream urine samples were collected from 56 patients with histologically confirmed prostate cancer. A control group was formed with 53 healthy male volunteers matched for age who had recently undergone a negative screening by prostate-specific antigen (PSA) and digital rectal exam. Headspace measurements were performed with the electronic nose Cyranose 320
RESULTS
RESULTS
The electronic nose yielded a sensitivity of 77% and specificity of 62%. Mahalanobis distance was 0.964, which is indicative of limited group separation. IMS identified a total of 38 individual analytical peaks, two of which showed significant differences between groups (p < 0.05). To discriminate between tumor and controls, a decision tree with nine steps was generated. This model led to a sensitivity of 98% and specificity of 100%.
CONCLUSIONS
CONCLUSIONS
VOC-based detection of prostate cancer seems feasible in principle. While the first results with an electronic nose show some limitations, the approach can compete with other urine-based marker systems. However, it seems less reliable than PSA testing. IMS is more accurate than the electronic nose with promising sensitivity and specificity, which warrants further research. The individual relevant metabolites identified by IMS should further be characterized using gas chromatography/mass spectrometry to facilitate potential targeted rapid testing.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. The Prostate published by Wiley Periodicals LLC.
Références
Krebs in Deutschland [Cancer in Germany] 2017/2018: Robert-Koch-Institut; 2021.
Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate Cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243-262.
Boehm BE, York ME, Petrovics G, Kohaar I, Chesnut GT. Biomarkers of aggressive prostate cancer at diagnosis. Int J Mol Sci. 2023;24(3):2185.
Hattesohl ADM, Jörres RA, Dressel H, et al. Discrimination between COPD patients with and without alpha 1-antitrypsin deficiency using an electronic nose. Respirology. 2011;16(8):1258-1264.
Greulich T, Hattesohl A, Grabisch A, et al. Detection of obstructive sleep apnoea by an electronic nose. Eur Respir J. 2013;42(1):145-155.
de Heer K, Kok MGM, Fens N, et al. Detection of airway colonization by Aspergillus fumigatus by use of electronic nose technology in patients with cystic fibrosis. J Clin Microbiol. 2016;54(3):569-575.
Bach JP, Gold M, Mengel D, et al. Measuring compounds in exhaled air to detect Alzheimer's disease and Parkinson's disease. PLoS One. 2015;10(7):e0132227.
Peng G, Hakim M, Broza YY, et al. Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. Br J Cancer. 2010;103(4):542-551.
de Meij TG, de Boer NK, Benninga MA, et al. Faecal gas analysis by electronic nose as novel, non-invasive method for assessment of active and quiescent paediatric inflammatory bowel disease: proof of principle study. J Crohns Colitis. 2014:S1873-9946(14)00285-2.
Probert CS, Reade S, Ahmed I. Fecal volatile organic compounds: a novel, cheaper method of diagnosing inflammatory bowel disease? Expert Rev Clin Immunol. 2014;10(9):1129-1131.
Heers H, Gut JM, Hegele A, et al. Non-invasive detection of bladder tumors through volatile organic compounds: a pilot study with an electronic nose. Anticancer Res. 2018;38(2):833-837.
Asimakopoulos AD, Del Fabbro D, Miano R, et al. Prostate cancer diagnosis through electronic nose in the urine headspace setting: a pilot study. Prostate Cancer Prostatic Dis. 2014;17(2):206-211.
Taverna G, Grizzi F, Tidu L, et al. Accuracy of a new electronic nose for prostate cancer diagnosis in urine samples. Int J Urol. 2022;29(8):890-896.
Talens JB, Pelegri-Sebastia J, Sogorb T, Ruiz JL. Prostate cancer detection using e-nose and AI for high probability assessment. BMC Med Inform Decis Mak. 2023;23(1):205.
Filianoti A, Costantini M, Bove AM, et al. Volatilome analysis in prostate cancer by electronic nose: a pilot monocentric study. Cancers. 2022;14(12):2927.
Waltman CG, Marcelissen TAT, van Roermund JGH. Exhaled-breath testing for prostate cancer based on volatile organic compound profiling using an electronic nose device (Aeonose): a preliminary report. Eur Urol Focus. 2020;6(6):1220-1225.
Roine A, Tolvanen M, Sipiläinen M, et al. Detection of smell print differences between nonmalignant and malignant prostate cells with an electronic nose. Future Oncol. 2012;8(9):1157-1165.
Zang X, Monge ME, Gaul DA, Fernández FM. Flow injection-traveling-wave ion mobility-mass spectrometry for prostate-cancer metabolomics. Anal Chem. 2018;90(22):13767-13774.
Liu Q, Fan Y, Zeng S, et al. Volatile organic compounds for early detection of prostate cancer from urine. Heliyon. 2023;9(6):e16686.
Tyagi H, Daulton E, Bannaga AS, Arasaradnam RP, Covington JA. Urinary volatiles and chemical characterisation for the non-invasive detection of prostate and bladder cancers. Biosensors. 2021;11(11):437.
Deev V, Solovieva S, Andreev E, et al. Prostate cancer screening using chemometric processing of GC-MS profiles obtained in the headspace above urine samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2020;1155:122298.
Gao Q, Su X, Annabi MH, et al. Application of urinary volatile organic compounds (VOCs) for the diagnosis of prostate cancer. Clin Genitourin Cancer. 2019;17(3):183-190.
Khalid T, Aggio R, White P, et al. Urinary volatile organic compounds for the detection of prostate cancer. PLoS One. 2015;10(11):e0143283.
Woollam M, Siegel AP, Munshi A, et al. Canine-inspired chemometric analysis of volatile organic compounds in urine headspace to distinguish prostate cancer in mice and men. Cancers. 2023;15(4):1352.
Cornu JN, Cancel-Tassin G, Ondet V, Girardet C, Cussenot O. Olfactory detection of prostate cancer by dogs sniffing urine: a step forward in early diagnosis. Eur Urol. 2011;59(2):197-201.
Guest C, Harris R, Sfanos KS, et al. Feasibility of integrating canine olfaction with chemical and microbial profiling of urine to detect lethal prostate cancer. PLoS One. 2021;16(2):e0245530.
Bryant RJ, Sjoberg DD, Vickers AJ, et al. Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. J Natl Cancer Inst. 2015;107(7):djv095.
de la Calle C, Patil D, Wei JT, et al. Multicenter evaluation of the prostate health index to detect aggressive prostate cancer in biopsy naïve men. J Urol. 2015;194(1):65-72.
Catalona WJ, Partin AW, Sanda MG, et al. A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range. J Urol. 2011;185(5):1650-1655.
Nordström T, Vickers A, Assel M, Lilja H, Grönberg H, Eklund M. Comparison between the four-kallikrein panel and prostate health index for predicting prostate cancer. Eur Urol. 2015;68(1):139-146.
Ploussard G, de la Taille A. The role of prostate cancer antigen 3 (PCA3) in prostate cancer detection. Expert Rev Anticancer Ther. 2018;18(10):1013-1020.
Van Neste L, Hendriks RJ, Dijkstra S, et al. Detection of high-grade prostate cancer using a urinary molecular biomarker-based risk score. Eur Urol. 2016;70(5):740-748.
Maggi M, Del Giudice F, Falagario UG, et al. SelectMDx and multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy: a prospective assessment in a multi-institutional study. Cancers. 2021;13(9):2047.